

Chandrajit P Raut

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1099491/publications.pdf>

Version: 2024-02-01

141
papers

8,282
citations

46918

47
h-index

49773

87
g-index

151
all docs

151
docs citations

151
times ranked

9364
citing authors

#	ARTICLE	IF	CITATIONS
1	Postnephrectomy outcomes following <i>en bloc</i> resection of primary retroperitoneal sarcoma: multicentre study. <i>British Journal of Surgery</i> , 2022, 109, 165-168.	0.1	3
2	So Now What? Unanswered Questions Regarding Retroperitoneal Sarcomas, Hospital Volume, Multidisciplinary Expertise, and Outcomes. <i>Annals of Surgical Oncology</i> , 2022, 29, 2138.	0.7	0
3	Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. <i>Clinical Cancer Research</i> , 2022, 28, 2397-2408.	3.2	6
4	Use of Neoadjuvant Imatinib to Facilitate Minimally Invasive Resection of Gastric Gastrointestinal Stromal Tumors. <i>Annals of Surgical Oncology</i> , 2022, 29, 7104-7113.	0.7	2
5	Abstract 5648: Response and resistance to CDK2 and CDK4/6 inhibition in GIST. <i>Cancer Research</i> , 2022, 82, 5648-5648.	0.4	0
6	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2022, 29, 7335-7348.	0.7	13
7	Primary intraâ€abdominal melanoma arising in association with extracutaneous blue naevus: a report of two cases. <i>Histopathology</i> , 2021, 78, 281-289.	1.6	3
8	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVIDâ€19 pandemic: A guide for surgical oncologists. <i>Journal of Surgical Oncology</i> , 2021, 123, 12-23.	0.8	7
9	Nephrectomy for Retroperitoneal Sarcoma: Stay Calm and (Cautiously) Carry On. <i>Annals of Surgical Oncology</i> , 2021, 28, 1275-1277.	0.7	1
10	Defining the role of neoadjuvant systemic therapy in highâ€risk retroperitoneal sarcoma: A multiâ€institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738.	2.0	30
11	Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15Âyears. <i>Annals of Surgical Oncology</i> , 2021, 28, 1700-1709.	0.7	38
12	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 6882-6889.	0.7	14
13	Traveling to Receive Treatment for Extremity Soft Tissue Sarcomas: Is it worth the drive?. <i>World Journal of Surgery</i> , 2021, 45, 2415-2425.	0.8	0
14	Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program. <i>Current Opinion in Oncology</i> , 2021, 33, 301-308.	1.1	13
15	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 7854-7863.	0.7	19
16	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
17	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 7873-7888.	0.7	105
18	ASO Author Reflections: Selecting Patients for Recurrent Retroperitoneal Sarcoma Surgery: The Challenging Trade-Off Between Oncologic Outcome and Morbidity. <i>Annals of Surgical Oncology</i> , 2021, 28, 852-853.	0.7	1

#	ARTICLE	IF	CITATIONS
19	ASO Visual Abstract: An Analysis of Differentiation Changes and Outcomes at the First Recurrence of Retroperitoneal Liposarcoma by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 490-491.	0.7	4
20	Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. <i>European Journal of Cancer</i> , 2021, 157, 291-300.	1.3	11
21	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 2705-2714.	0.7	26
22	Characteristics of atypical postradiation vascular proliferation: A retrospective review of 193 patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1447-1450.	0.6	7
23	Desmoid tumors: To treat or not to treat, That is the question. <i>Cancer</i> , 2020, 126, 5213-5221.	2.0	43
24	Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. <i>Molecular Cancer Research</i> , 2020, 18, 1302-1314.	1.5	24
25	The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors. <i>Annals of Surgical Oncology</i> , 2020, 27, 3659-3671.	0.7	11
26	Virtual Interviews for the Complex General Surgical Oncology Fellowship: The Dana-Farber/Partners Experience. <i>Annals of Surgical Oncology</i> , 2020, 27, 3103-3106.	0.7	21
27	Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. <i>Cancer</i> , 2020, 126, 4917-4925.	2.0	21
28	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1366-1377.	5.1	266
29	Virtual Biobanking for Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Initiative. <i>Annals of Surgical Oncology</i> , 2020, 27, 3573-3576.	0.7	2
30	The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. <i>Nature Medicine</i> , 2020, 26, 181-187.	15.2	158
31	Racial Differences in Extremity Soft Tissue Sarcoma Treatment in a Universally Insured Population. <i>Journal of Surgical Research</i> , 2020, 250, 125-134.	0.8	8
32	Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. <i>Cancer</i> , 2020, 126, 3002-3012.	2.0	39
33	Enhanced recovery after surgery pathway in patients with soft tissue sarcoma. <i>British Journal of Surgery</i> , 2020, 107, e568.	0.1	1
34	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	1.3	243
35	To Biopsy, or Not to Biopsy: Is There Really a Question?. <i>Annals of Surgical Oncology</i> , 2019, 26, 4182-4184.	0.7	5
36	Screening populations at high risk for soft tissue sarcoma and surveillance following soft tissue sarcoma resection. <i>Journal of Surgical Oncology</i> , 2019, 120, 882-890.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 5135-5142.	3.2	14
38	The opportunities and shortcomings of using big data and national databases for sarcoma research. <i>Cancer</i> , 2019, 125, 2926-2934.	2.0	38
39	Defining Rupture in Gastrointestinal Stromal Tumor: Semantics and Prognostic Value. <i>Annals of Surgical Oncology</i> , 2019, 26, 2304-2305.	0.7	5
40	Defining Tumor Rupture in Gastrointestinal Stromal Tumor. <i>Annals of Surgical Oncology</i> , 2019, 26, 1669-1675.	0.7	54
41	Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). <i>Clinical Sarcoma Research</i> , 2019, 9, 3.	2.3	26
42	Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 153, 471-478.	0.6	18
43	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019, 25, 2664-2671.	3.2	80
44	A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 425-435.	0.4	28
45	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2019, 120, 612-620.	2.9	109
46	New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration. <i>Current Opinion in Oncology</i> , 2019, 31, 310-316.	1.1	53
47	Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. <i>JCO Precision Oncology</i> , 2019, 2019, 1-11.	1.5	31
48	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2019, 125, 1290-1300.	2.0	71
49	Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. <i>Cancer Research</i> , 2019, 79, 994-1009.	0.4	17
50	STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11001-11001.	0.8	64
51	The impact of lipomatous tumors on type 2 diabetes: are adipose-derived tumors metabolically active?. <i>Journal of Surgical Research</i> , 2018, 222, 48-54.	0.8	3
52	Current principles of surgery for retroperitoneal sarcomas. <i>Journal of Surgical Oncology</i> , 2018, 117, 33-41.	0.8	56
53	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2018, 267, 959-964.	2.1	142
54	Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors. <i>Annals of Surgery</i> , 2018, 268, 296-302.	2.1	58

#	ARTICLE	IF	CITATIONS
55	Surgical Management of Primary Retroperitoneal Sarcomas: Rationale for Selective Organ Resection. <i>Annals of Surgical Oncology</i> , 2018, 25, 98-106.	0.7	65
56	Amputation for Extremity Sarcoma: Contemporary Indications and Outcomes. <i>Annals of Surgical Oncology</i> , 2018, 25, 394-403.	0.7	34
57	Amputation for Sarcoma: Revisiting a 19th Century Treatment in the 21st Century. <i>Annals of Surgical Oncology</i> , 2018, 25, 351-353.	0.7	3
58	Cutaneous Breast Radiation-associated Angiosarcoma: Anterior Chest Wall Reconstruction Options Following Extra-radical Resection. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2018, 6, e1938.	0.3	3
59	ASO Author Reflections: Rationale for Organ Resection for Retroperitoneal Sarcomas. <i>Annals of Surgical Oncology</i> , 2018, 25, 940-941.	0.7	2
60	Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy. <i>BMC Cancer</i> , 2018, 18, 1296.	1.1	21
61	A call to action: Why sarcoma surgery needs to be centralized. <i>Cancer</i> , 2018, 124, 4452-4454.	2.0	13
62	Gastrointestinal Stromal Tumors. <i>Visceral Medicine</i> , 2018, 34, 376-379.	0.5	4
63	Tumor Biological Aspects of Epithelial versus Mesenchymal Tumors of the Gastrointestinal Tract. <i>Visceral Medicine</i> , 2018, 34, 342-346.	0.5	2
64	Gastrointestinal Stromal Tumors. <i>Visceral Medicine</i> , 2018, 34, 332-333.	0.5	2
65	Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 488-505.	157.7	211
66	Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor. <i>JAMA Oncology</i> , 2018, 4, e184060.	3.4	112
67	Minimally Invasive Surgery for Retroperitoneal Sarcoma: Just Because We Can Does Not Mean We Should. <i>Annals of Surgical Oncology</i> , 2018, 25, 2129-2131.	0.7	6
68	Assessment of the Accuracy of Disease Coding Among Patients Diagnosed With Sarcoma. <i>JAMA Oncology</i> , 2018, 4, 1293.	3.4	10
69	Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5746-E5755.	3.3	20
70	Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Transatlantic RPS Working Group. <i>Cancer</i> , 2017, 123, 1971-1978.	2.0	104
71	Surveillance Imaging Patterns and Outcomes Following Radiation Therapy and Radical Resection for Localized Extremity and Trunk Soft Tissue Sarcoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 1588-1595.	0.7	19
72	Incidence and Adverse Prognostic Implications of Histopathologic Organ Invasion in Primary Retroperitoneal Sarcoma. <i>Journal of the American College of Surgeons</i> , 2017, 224, 876-883.	0.2	38

#	ARTICLE	IF	CITATIONS
73	Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for Research and Treatment of Cancerâ€“Soft Tissue and Bone Sarcoma Group Response Score. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 375-383.	0.4	65
74	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. <i>Immunity</i> , 2017, 46, 197-204.	6.6	400
75	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. <i>Nature Communications</i> , 2017, 8, 14674.	5.8	53
76	Soft tissue sarcoma nomograms and their incorporation into practice. <i>Cancer</i> , 2017, 123, 2802-2820.	2.0	105
77	A Rational Approach to Surgery for Retroperitoneal Sarcomas: Extent of Resection Tailored to Histologic Findings. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 273.	0.4	1
78	Management of Gastrointestinal Stromal Tumors. <i>Surgical Clinics of North America</i> , 2017, 97, 437-452.	0.5	35
79	Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy. <i>Oncologist</i> , 2017, 22, 1265-1270.	1.9	24
80	Costâ€“Effectiveness of Surveillance for Distant Recurrence in Extremity Soft Tissue Sarcoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 3264-3270.	0.7	13
81	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	13.5	738
82	Title is missing!, 2017, , .		4
83	Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS). <i>Annals of Surgery</i> , 2016, 263, 1002-1009.	2.1	392
84	External validation of a multiâ€“institutional retroperitoneal sarcoma nomogram. <i>Cancer</i> , 2016, 122, 1417-1424.	2.0	77
85	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	2.0	82
86	Acute gastrointestinal toxicity and bowel bag dose-volume parameters for preoperative radiation therapy for retroperitoneal sarcoma. <i>Practical Radiation Oncology</i> , 2016, 6, 360-366.	1.1	19
87	Preface. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, xv-xvii.	0.6	0
88	Surgical Management of Metastatic Disease. <i>Surgical Clinics of North America</i> , 2016, 96, 1175-1192.	0.5	10
89	The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors. <i>Current Treatment Options in Oncology</i> , 2016, 17, 8.	1.3	27
90	Musical preference correlates closely to professional roles and specialties in operating room: A multicenter cross-sectional cohort study with 672 participants. <i>Surgery</i> , 2016, 159, 1260-1268.	1.0	21

#	ARTICLE	IF	CITATIONS
91	Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: Genomic, neoantigen, and immunohistochemical evaluation.. Journal of Clinical Oncology, 2016, 34, 11043-11043.	0.8	4
92	Conjoined hyperactivation of the RAS and PI3K pathways in advanced GIST.. Journal of Clinical Oncology, 2016, 34, e22520-e22520.	0.8	7
93	MRI findings of radiation-associated angiosarcoma of the breast (RAS). Journal of Magnetic Resonance Imaging, 2015, 42, 763-770.	1.9	31
94	Safety and Efficacy of Radiation Dose Delivered via Iodine-125 Brachytherapy Mesh Implantation for Deep Cavity Sarcomas. Annals of Surgical Oncology, 2015, 22, 1455-1463.	0.7	18
95	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186.	3.2	34
96	Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis.. Journal of Clinical Oncology, 2015, 33, 10537-10537.	0.8	4
97	Postoperative morbidity and mortality in a large series of primary retroperitoneal sarcoma (RPS) treated at 8 tertiary centers: A study from the Transatlantic RPS Working Group.. Journal of Clinical Oncology, 2015, 33, 10557-10557.	0.8	0
98	High-dose-rate Interstitial Brachytherapy Boost with a Pedicled Latissimus Dorsi Myocutaneous Flap for Myxofibrosarcoma of the Arm. Plastic and Reconstructive Surgery - Global Open, 2014, 2, e229.	0.3	2
99	The economic impact of cytoreductive surgery and tyrosine kinase inhibitor therapy in the treatment of advanced gastrointestinal stromal tumours: A Markov chain decision analysis. European Journal of Cancer, 2014, 50, 397-405.	1.3	2
100	Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery. Journal of the American College of Surgeons, 2014, 218, 206-217.	0.2	99
101	Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics, 2014, 46, 601-606.	9.4	142
102	Locoregional Recurrence After Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Adverse Impact of Multifocal Disease and Potential Implications of Dose Escalation. Annals of Surgical Oncology, 2013, 20, 2140-2147.	0.7	54
103	Cytoreductive Surgery in Advanced GIST: Timing is Everything. Annals of Surgical Oncology, 2013, 20, 4059-4060.	0.7	7
104	External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer, 2013, 119, 1816-1822.	2.0	54
105	In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2013, 31, 10510-10510.	0.8	5
106	Demonstration of gender-specific variability in a pharmacokinetic (PK) analysis of the PERSIST-5 trial of adjuvant imatinib (IM) for patients with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence.. Journal of Clinical Oncology, 2013, 31, 10538-10538.	0.8	1
107	Modern Surgical Therapy: Limb Salvage and the Role of Amputation for Extremity Soft-Tissue Sarcomas. Surgical Oncology Clinics of North America, 2012, 21, 201-213.	0.6	42
108	Technical Considerations in Surgery for Retroperitoneal Sarcomas: Position Paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTC-STBSG. Annals of Surgical Oncology, 2012, 19, 2981-2991.	0.7	212

#	ARTICLE	IF	CITATIONS
109	Paclitaxel-Eluting Polymer Film Reduces Locoregional Recurrence and Improves Survival in a Recurrent Sarcoma Model: A Novel Investigational Therapy. <i>Annals of Surgical Oncology</i> , 2012, 19, 199-206.	0.7	44
110	The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones. <i>Annals of Surgical Oncology</i> , 2012, 19, 1051-1055.	0.7	27
111	Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). <i>PLoS ONE</i> , 2012, 7, e26331.	1.1	39
112	Desmoid fibromatosis and pregnancy: A multi-institutional analysis of recurrence and obstetric risk.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10017-10017.	0.8	0
113	External validation of a nomogram predicting overall survival (OS) of women with uterine leiomyosarcoma (ULMS).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5090-5090.	0.8	0
114	Features of familiarity in a cohort of patients (pts) with sarcoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1547-1547.	0.8	0
115	Targeted Therapy in Advanced Well-Differentiated Neuroendocrine Tumors. <i>Oncologist</i> , 2011, 16, 286-295.	1.9	15
116	Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate. <i>Annals of Surgical Oncology</i> , 2010, 17, 407-415.	0.7	74
117	Are Radical Compartmental Resections for Retroperitoneal Sarcomas Justified?. <i>Annals of Surgical Oncology</i> , 2010, 17, 1481-1484.	0.7	56
118	Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. <i>European Journal of Cancer</i> , 2009, 45, 2818-2824.	1.3	44
119	Predictors of Survival After Resection of Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2009, 250, 970-976.	2.1	137
120	Controversies in the surgical management of GIST in the era of imatinib. <i>Oncology</i> , 2009, 23, 69, 74-6.	0.4	0
121	How I Do It: Surgical Management of Gastrointestinal Stromal Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1592-1599.	0.9	36
122	Evidence-Guided Surgical Management of GIST: Beyond a Simple Case of Benign and Malignant. <i>Annals of Surgical Oncology</i> , 2008, 15, 1542-1543.	0.7	5
123	Review. <i>Gastroenterology and Hepatology</i> , 2008, 4, 657-9.	0.2	0
124	Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2007, 246, 52-60.	2.1	508
125	Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease. <i>Current Opinion in Gastroenterology</i> , 2007, 23, 149-158.	1.0	46
126	Leiomyosarcoma of the Inferior Vena Cava: Survival After Aggressive Management. <i>Annals of Surgical Oncology</i> , 2007, 14, 3534-3541.	0.7	108

#	ARTICLE	IF	CITATIONS
127	Intraductal Papillary Mucinous Neoplasms of the Pancreas: Effect of Invasion and Pancreatic Margin Status on Recurrence and Survival. <i>Annals of Surgical Oncology</i> , 2006, 13, 582-594.	0.7	130
128	In Brief. <i>Current Problems in Surgery</i> , 2006, 43, 383-388.	0.6	32
129	Retroperitoneal sarcomas: Combined-modality treatment approaches. <i>Journal of Surgical Oncology</i> , 2006, 94, 81-87.	0.8	114
130	Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2006, 24, 2325-2331.	0.8	396
131	Significant Long-Term Survival After Radiofrequency Ablation of Unresectable Hepatocellular Carcinoma in Patients with Cirrhosis. <i>Annals of Surgical Oncology</i> , 2005, 12, 616-628.	0.7	152
132	Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis. <i>Cancer</i> , 2005, 104, 692-699.	2.0	92
133	Colorectal Carcinogenesis: MSI-H Versus MSI-L. <i>Disease Markers</i> , 2004, 20, 199-206.	0.6	116
134	Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. <i>Cancer Biology and Therapy</i> , 2004, 3, 1217-1224.	1.5	55
135	Direct effects of recombinant human endostatin on tumor cell IL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer. <i>Cancer Biology and Therapy</i> , 2004, 3, 679-687.	1.5	77
136	Clinicopathologic features in colorectal cancer patients with microsatellite instability. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2004, 568, 275-282.	0.4	78
137	Surgical Management of Popliteal Artery Embolism at the Turn of the Millennium. <i>Annals of Vascular Surgery</i> , 2004, 18, 79-85.	0.4	5
138	Unusual functioning endocrine tumors. <i>Current Treatment Options in Oncology</i> , 2004, 5, 327-334.	1.3	1
139	Neoadjuvant therapy for resectable pancreatic cancer. <i>Surgical Oncology Clinics of North America</i> , 2004, 13, 639-661.	0.6	47
140	Diagnostic Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Patients With Presumed Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2003, 7, 118-128.	0.9	248
141	Giant Lipoma of the Pancreas: Case Report and Review of Lipomatous Lesions of the Pancreas. <i>Pancreas</i> , 2003, 26, 97-99.	0.5	23